Technologies that can harness the power of RNA-targeted therapeutics have the potential to transform the way we treat diseases, resulting in new blueprints for future medicines.
// Our Competitive Edge
We have a novel discovery platform to identify new RNA drugs on a scale and throughput that is currently inaccessible to the state-of-the-art.
Our computational workflow can transform pre-existing drugs into new, proprietary molecules with improved properties.
// We Are
// Recent News
InFocus was selected amongst over 1,300 startups into the prestigious Berkeley SkyDeck Pad-13 Program. Our CSO will represent the company to join the three-months program starting in May 2024. As a Pad-13 member, the InFocus team receives exclusive access to world-class resources from the SkyDeck Program as well as the faculty and alumni network of UC Berkeley.
Our efforts to develop innovative RNA-targeting small molecule therapeutics for patients in oncology will be greatly accelerated by PSCC’s top experts in the academic-to-industry continuum, with comprehensive network and infrastructure to data, technologies, laboratories and funding support.
This is an exciting opportunity to showcase our talented team and computation-powered R&D strategy before ~100 of the most active European and international life science investors.
The InFocus team is excited to convene at the annual JP Morgan Healthcare Week, the annual industry-leading event which sets the tone for the entire year.
Our Team will be at the RNA-Targeted Drug Discovery & Development Summit, exploring collaborations with innovative platforms, technology experts and scientific KOLs.
InFocus is proud to be accepted into the selective Founder Institute's Silicon Valley Flagship Program, the world's leading pre-seed startup accelerator.
We are proud members of:
// Contact
